BeOne Medicines AG (SHA:688235)
China flag China · Delayed Price · Currency is CNY
257.70
-5.74 (-2.18%)
At close: Feb 27, 2026

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13
U.S. Revenue
2.88B1.96B
U.S. Revenue Growth
47.14%73.50%
China Revenue
1.68B1.41B
China Revenue Growth
19.00%28.07%
Europe Revenue
611.37M362.63M
Europe Revenue Growth
68.59%79.51%
Rest of World Revenue
171.81M78.81M
Rest of World Revenue Growth
118.00%196.33%
Revenue (Total)
5.34B3.81B
Revenue (Total) Growth
40.23%54.96%

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13
BRUKINSA Revenue
3.93B2.64B
BRUKINSA Revenue Growth
48.57%104.92%
TEVIMBRA Revenue
737.30M620.84M
TEVIMBRA Revenue Growth
18.76%15.69%
XGEVA Revenue
305.98M224.40M
XGEVA Revenue Growth
36.35%141.74%
BLINCYTO Revenue
104.22M74.33M
BLINCYTO Revenue Growth
40.22%36.78%
KYPROLIS Revenue
74.97M66.17M
KYPROLIS Revenue Growth
13.30%66.26%
POBEVCY Revenue
47.40M53.51M
POBEVCY Revenue Growth
-11.42%-5.37%
REVLIMID Revenue
-36.03M
REVLIMID Revenue Growth
--52.61%
Other Product Revenue
-60.04M
Other Product Revenue Growth
-38.66%
Total Other Product Revenue
83.69M96.07M
Total Other Product Revenue Growth
-12.88%-19.48%
Total Product Revenue
5.28B3.78B
Total Product Revenue Growth
39.75%72.59%
Collaboration Revenue
60.97M30.70M
Collaboration Revenue Growth
98.64%-88.59%
Revenue (Total)
5.34B3.81B
Revenue (Total) Growth
40.23%54.96%
Updated Dec 31, 2025. Data Source: Fiscal.ai.